Clinical Trial Update: Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating an imaging biomarker for hepatic fibrosis using the contrast agent gadoxetate disodium; current status is not specified…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Fibrosis

Drugs mentioned

• Gadoxetate disodium (gadoxetate disodium)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Hepatic Fibrosis | Phase 4 | Status: UNKNOWN